Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-11-14
DOI
10.1038/srep36694
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
- (2016) Naomi B Haas et al. LANCET
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Biomarkers of residual disease after neoadjuvant therapy for breast cancer
- (2016) Frederique Penault-Llorca et al. Nature Reviews Clinical Oncology
- Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
- (2015) Véronique Diéras et al. BREAST
- Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy
- (2015) M. Paez-Ribes et al. CLINICAL CANCER RESEARCH
- A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2015) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis
- (2015) Bin-Zhi Qian et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
- (2015) Helena M Earl et al. LANCET ONCOLOGY
- Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
- (2015) Harry D Bear et al. LANCET ONCOLOGY
- VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells
- (2015) X. Ye et al. MOLECULAR CANCER RESEARCH
- Amgen's angiopoietin blocker fails in ovarian cancer
- (2015) Cormac Sheridan NATURE BIOTECHNOLOGY
- Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth
- (2014) Kshitij Srivastava et al. CANCER CELL
- Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
- (2014) J. M. Ebos et al. EMBO Molecular Medicine
- Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs
- (2013) E. Guerin et al. CANCER RESEARCH
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
- (2012) Nicholas Papadopoulos et al. ANGIOGENESIS
- Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
- (2012) C. Daly et al. CANCER RESEARCH
- VEGF and Angiopoietin-1 exert opposing effects on cell junctions by regulating the Rho GEF Syx
- (2012) Siu P. Ngok et al. JOURNAL OF CELL BIOLOGY
- Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
- (2012) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Fighting Fire with Fire: Rekindling the Bevacizumab Debate
- (2012) Alberto J. Montero et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orchestral actions of angiopoietin-1 in vascular regeneration
- (2012) Gou Young Koh TRENDS IN MOLECULAR MEDICINE
- Reappraising antiangiogenic therapy for breast cancer
- (2011) Robert S. Kerbel BREAST
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Angiopoietin-1 Overexpression Modulates Vascular Endothelium to Facilitate Tumor Cell Dissemination and Metastasis Establishment
- (2009) T. Holopainen et al. CANCER RESEARCH
- Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
- (2009) Y. Cao Science Signaling
- Angiopoietin-1 Prevents VEGF-Induced Endothelial Permeability by Sequestering Src through mDia
- (2008) Julie Gavard et al. DEVELOPMENTAL CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started